Scholtz & Company’s Biogen BIIB Stock Holding History

Scholtz & Company’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-4,362	Closed	-$1.76M	–	47
2015 Q2	$1.76M	Buy	+4,362	New	+$1.75M	1.73%	25

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Scholtz & Company's BIIB Position: Q3 2015 in Review

Scholtz & Company sold out of Biogen (BIIB) in Q3 2015, closing a stake of 4,362 shares — an estimated $1.76M sold.

Scholtz & Company first reported a position in BIIB in Q2 2015 and held it in 1 quarter. The position peaked at $1.76M in Q2 2015. 924 funds tracked by Wall St. Rank hold BIIB as of Q3 2015.

Scholtz & Company reported no remaining Biogen position as of Q3 2015 after selling out during the quarter.
Scholtz & Company sold 4,362 Biogen shares in Q3 2015, an estimated $1.76M.
Scholtz & Company first reported a position in Biogen in Q2 2015 and held it in 1 quarter.
Scholtz & Company's Biogen position peaked at $1.76M in Q2 2015.
924 funds tracked by Wall St. Rank held Biogen as of Q3 2015.

Based on Scholtz & Company's 13F filing for Q3 2015, filed 12 Nov 2015.